Evaluation of Safety and Effectiveness on Oral Anticoagulants

Retrospective Medical Chart Review Study for Atrial Fibrillation Patents Treated With Oral Anticoagulant

This study is to compare the risk of major bleeding among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating treatment

Inclusion Criteria:

• Individuals greater than or equal to 20 years old as of the index date
• At least 1 diagnosis of NVAF prior to or on index date, identified by any medical records
• Newly treated with warfarin or apixaban between 01-Jan-2011 to 31-Dec-2016. The first warfarin or apixaban prescription date during the identification period will be designated as the index date

Exclusion Criteria:

• Patient's medical records indicating pregnancy during the follow-up period
• Patient's medical records indicating taking warfarin, apixaban, dabigatran, rivaroxaban, or edoxaban during the 6-months prior to the index date
• Had > 1 OAC prescription in the patient's medical records on the index date

Other protocol defined inclusion/exclusion criteria could apply